amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate
ADDERALL 30 (amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate) by Teva is non-catecholamine sympathomimetic amines with cns stimulant activity. Approved for attention deficit hyperactivity disorder (adhd) in patients 13 years, older [see clinical studies ()], older and 1 more indications. First approved in 1960.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
Adderall 30 is an oral tablet containing a fixed-dose combination of amphetamine salts (amphetamine aspartate, amphetamine sulfate, dextroamphetamine saccharate, and dextroamphetamine sulfate) approved for ADHD in patients 13 years and older. It is a non-catecholamine sympathomimetic amine with CNS stimulant activity; the exact mechanism of therapeutic action in ADHD remains unknown. The drug works by increasing norepinephrine and dopamine signaling in the central nervous system.
As LOE approaches, the brand faces declining market exclusivity; commercial teams should expect portfolio consolidation and transition to generic support models.
non-catecholamine sympathomimetic amines with CNS stimulant activity. The exact mode of therapeutic action in ADHD is not known.
Worked on ADDERALL 30 at Teva? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on Adderall 30 means joining a stable, mature product with limited growth runway but essential market infrastructure. Roles focus on generic competition management, channel optimization, and brand defense rather than innovation or expansion. This is an ideal transition role for professionals seeking operational depth in a controlled-substance environment without high-stakes R&D pressure.